Details of Disease

General Information of Disease (ID: DIS57XO9)

• Disease Name: Lymphatic disease
• Synonyms: adenopathy; lympoid system disease; disease of lympoid system; disorder of lymphoid system; lymphadenopathy; lymphangiopathy; swollen gland; disorder of lymphatic system; lymphatic part of lymphoid system disease; disorder of lymphatic part of lymphoid system; disorder of lymph node and lymphatics; lymphatic part of lymphoid system disease or disorder; lymphatic disorder; lymphatic disease; swollen glands; glands, swollen; disease or disorder of lymphatic part of lymphoid system; disease of lymphatic part of lymphoid system
• Disease Class: BD9Z: Lymphatic vessel/lymph nodes disorder
• Definition: A disease involving the lymphatic part of lymphoid system.|Editor note: check alignment to anatomy, consider lymphoid system disease
• Disease Hierarchy:
  DIS20IIA: Lymphoid system disorder
  DISWD40R: Disease
  DIS57XO9: Lymphatic disease
• ICD Code:
  ICD-11: ICD-11: BD9Z
  Expand ICD-11: 'BD9Z
  Expand ICD-10: 'I89; 'I89.8; 'I89.9
• Disease Identifiers:
  MONDO ID: MONDO_0005833
  UMLS CUI: C4021976
  MedGen ID: 892707
  HPO ID: HP:0100763

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ethiodized oil	DMRVWZW	Approved	NA	[1]
Medium chain triglycerides	DMY0HZA	Approved	NA	[1]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CAR.CD30 cells	DM6ZXWY	Phase 1/2	CAR T Cell Therapy	[2]
ATLCAR.CD30 cells	DMZI4UX	Phase 1	CAR T Cell Therapy	[3]
ATLCAR.CD30.CCR4 cells	DM3IPSX	Phase 1	CAR T Cell Therapy	[3]
HuCART-meso cells	DM4F8AU	Phase 1	CAR T Cell Therapy	[4]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ad VEGF-C	DMKFSNG	Investigative	NA	[5]
Entelon	DMVJPBD	Investigative	NA	[5]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
• [3] ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
• [4] ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
• [5] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.